Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T3E 7M8
- Pfizer Investigational Site
-
Edmonton, Alberta, Canada, T5H 3V9
- Pfizer Investigational Site
-
Edmonton, Alberta, Canada, T5H 0X5
- Pfizer Investigational Site
-
-
British Columbia
-
Nanaimo, British Columbia, Canada, V9R 5B6
- Pfizer Investigational Site
-
Vancouver, British Columbia, Canada, V6K 1V7
- Pfizer Investigational Site
-
Williams Lake, British Columbia, Canada, V2G 1H1
- Pfizer Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3C 0N2
- Pfizer Investigational Site
-
-
Nova Scotia
-
Sydney, Nova Scotia, Canada, B1P 1P2
- Pfizer Investigational Site
-
-
Ontario
-
Brampton, Ontario, Canada, L6V 1B4
- Pfizer Investigational Site
-
Hamilton, Ontario, Canada, L8M 1L6
- Pfizer Investigational Site
-
London, Ontario, Canada, N6A 4V2
- Pfizer Investigational Site
-
Mississauga, Ontario, Canada, L5L 1W8
- Pfizer Investigational Site
-
Oakville, Ontario, Canada, L6H 3P1
- Pfizer Investigational Site
-
Oakville, Ontario, Canada, L6L 5G8
- Pfizer Investigational Site
-
Toronto, Ontario, Canada, M4N 3M5
- Pfizer Investigational Site
-
Toronto, Ontario, Canada, M5T 2S8
- Pfizer Investigational Site
-
Toronto, Ontario, Canada, M5M 1B2
- Pfizer Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- Pfizer Investigational Site
-
Montreal, Quebec, Canada, H1V 1G5
- Pfizer Investigational Site
-
Sherbrooke, Quebec, Canada, J1K 1EB
- Pfizer Investigational Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7K 3H3
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects diagnosed at study visit or within 3 months of visit with OH
- OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma)
Exclusion Criteria:
- No prior treatment for OH or OAG
- No prior ocular surgery or history of ocular trauma
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
There is no intervention in this study
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
|
This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice.
Time Frame: duration of study
|
duration of study
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To describe the severity of disease at the time of diagnosis and to determine if there is a correlation between risk factors, or number of risk factors, and the severity of disease at presentation.
Time Frame: duration of study
|
duration of study
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A6111125
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.